The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

Nicola Edwards; Richard Steeds; Colin Chue; Paul Stewart; Charles Ferro; Jonathan Townend

doi:10.1111/j.1365-2125.2011.04102.x

The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

Nicola Edwards, Richard Steeds, Colin Chue, Paul Stewart, Charles Ferro, Jonathan Townend

Research output: Contribution to journal › Article

49 Citations (Scopus)

Abstract

WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of

Original language	English
Journal	British Journal of Clinical Pharmacology
DOIs	https://doi.org/10.1111/j.1365-2125.2011.04102.x
Publication status	Published - 28 Sept 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2125.2011.04102.x

Cite this

@article{8cf4899b294a4aa8b3a45f5dfd651dbc,

title = "The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.",

abstract = "WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of ",

author = "Nicola Edwards and Richard Steeds and Colin Chue and Paul Stewart and Charles Ferro and Jonathan Townend",

year = "2011",

month = sep,

day = "28",

doi = "10.1111/j.1365-2125.2011.04102.x",

language = "English",

journal = "British Journal of Clinical Pharmacology",

issn = "1365-2125",

publisher = "Wiley",

}

TY - JOUR

T1 - The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

AU - Edwards, Nicola

AU - Steeds, Richard

AU - Chue, Colin

AU - Stewart, Paul

AU - Ferro, Charles

AU - Townend, Jonathan

PY - 2011/9/28

Y1 - 2011/9/28

N2 - WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of

AB - WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of

U2 - 10.1111/j.1365-2125.2011.04102.x

DO - 10.1111/j.1365-2125.2011.04102.x

M3 - Article

C2 - 21950312

SN - 1365-2125

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

ER -

The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this